Harrow Health, Inc. (NASDAQ:HROW) CEO Buys $104,310.00 in Stock

Harrow Health, Inc. (NASDAQ:HROW) CEO Mark L. Baum purchased 9,000 shares of the company’s stock in a transaction on Friday, March 22nd. The stock was acquired at an average cost of $11.59 per share, for a total transaction of $104,310.00. Following the completion of the transaction, the chief executive officer now owns 2,137,525 shares in the company, valued at $24,773,914.75. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.

Harrow Health Price Performance

Shares of NASDAQ:HROW opened at $12.73 on Thursday. The company has a current ratio of 2.83, a quick ratio of 2.61 and a debt-to-equity ratio of 2.60. The business’s fifty day moving average price is $10.66 and its two-hundred day moving average price is $11.59. Harrow Health, Inc. has a fifty-two week low of $7.60 and a fifty-two week high of $28.25.

Analysts Set New Price Targets

A number of research firms have recently issued reports on HROW. B. Riley lowered their price objective on Harrow Health from $30.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, March 22nd. TheStreet cut Harrow Health from a “c-” rating to a “d+” rating in a research report on Tuesday, December 12th.

Hedge Funds Weigh In On Harrow Health

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Metropolitan Life Insurance Co NY acquired a new position in shares of Harrow Health during the second quarter valued at $27,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Harrow Health in the third quarter worth about $26,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Harrow Health in the 4th quarter valued at approximately $31,000. Ameritas Investment Partners Inc. acquired a new stake in Harrow Health in the 2nd quarter valued at approximately $41,000. Finally, Stonehage Fleming Financial Services Holdings Ltd bought a new position in Harrow Health in the third quarter valued at approximately $34,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Health Company Profile

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.